Xin-Wei Huang

Xin-Wei Huang

Auto-generated profile, based on publicly available information

Xin-Wei Huang

Department of Biostatistics State University of New York at Buffalo Buffalo New York USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2019 in Communications in Statistics - Simulation and Computation
Verified
Journal Article
Closed access
XHXin-Wei Huang
Xin-Wei Huang
Takeshi EmuraTakeshi Emura
Takeshi Emura
Investigating serial dependence is an important step in statistical process control (SPC). One recent approach is to fit a copula-based Markov chain model to perform SPC, which provides an attractive alternative to the traditional AR1 model. However, methodologies for model diagnostic have not been considered. In this paper, we develop two different approaches for model diagnostic procedures for copula-based Markov chain models. The first approach employs a formal test based on the Kolmogorov-Smirnov or the Cramér-von Mises statistics with aid of a parametric bootstrap. The second approach employs the second-order Markov chain model to examine the Markov property in the model. This second approach itself is a new SPC method. We made all the computing methodologies available in the R Copula.Markov package, and check their performance by simulations. We analyze three datasets for illustration.

1 March 2025 in JCO Oncology Practice
Verified
Journal Article
Closed access
AJAlfredo Viray Chua, Jr.
Alfredo Viray Chua, Jr.
JDJennifer Delmerico
Jennifer Delmerico
HSHaiyang Sheng
Haiyang Sheng
XHXin-Wei Huang
Xin-Wei Huang
ELEmily Liang
Emily Liang
SYSong Yao
Song Yao
PURPOSE: Minoritized racial/ethnic groups are historically under-represented in cancer clinical trials, which may be exacerbated in recent trials on immune checkpoint inhibitors (ICIs). We examined the representation and reporting of the racial/ethnic composition of participants in clinical trials on ICIs. METHODS: We examined English full-text trials on ICIs published from 2007 to 2022. Information on trial characteristics and racial/ethnic composition of participants was extracted from published papers or ClinicalTrials.gov. Differences in participation by publication year, ICI agent, and cancer site were analyzed. Enrollment-incidence ratio (EIR) was calculated to compare the proportion of minoritized racial/ethnic group patients in US-based trials against age-adjusted cancer incidence data available for the US population. An EIR > 1 signified over-representation, whereas an EIR <1 signified under-representation. RESULTS: Of the 471 trials examined, racial composition was unreported in 146 (31%), whereas Hispanic/Latinx ethnicity was unreported in 278 (59%). Only 30 (6%) trials reported race/ethnicity-specific results. In US-only trials (n = 174), White patients were over-represented (EIR, 1.20 [95% CI, 1.17 to 1.22]), whereas Hispanic/Latinx patients were the most under-represented (EIR, 0.35 [95% CI, 0.24 to 0.48]), followed by Black/African American patients (EIR, 0.66 [95% CI, 0.54 to 0.79]). Subgroup analyses consistently indicated over-representation of White patients across publication years (EIR, 1.19-1.24), ICI classes (EIR, 1.16-1.23), and cancer sites (EIR, 1.11-1.31), whereas Hispanic/Latinx patients were consistently under-represented. An upward trend of trial representation and reporting was observed for all minoritized racial/ethnic groups over time (trend P values ≤.05). CONCLUSION: Disparities in the representation and reporting of minoritized racial/ethnic groups persist in recent trials on ICIs, necessitating collaborative efforts for improved diversity and equitable cancer treatment access.


28 July 2024
Verified
Dataset
Closed access
XHXin-Wei Huang
Xin-Wei Huang